Bio-XL
Developing Biopharma solutionsto undertreated medical needs
Member of the @ARC innovation at Sheba
CancerPredict
Diagnostic test for improved cancer prognosis
Prediction allows preventive treatment, improve treatments outcomes, increase survival rate and improve quality of life
The test (addition to the current screening program) uses digital pathology method and
big data system assisted by AI.
Project funded by grant (pre-SEED)
CeaseCancer
Universal Anti-cancer drug
Alternative to chemotherapy
Personalized medicine leads to expensive cancer therapy, not accessible to most of people.
Chemotherapy, despite reluctance remains main drug treatment.
CeaseCancer, as a drug treatment with unique MoA, high safety profile and wide array of cancer types and stages, will enable replacement of chemo, or, in combination- reduce doses, to minimize adverse side effects
The first indications: TNBC and PDAC
Pre-SEED/SEED fund round now open
CancerPredict and CeaseCancer technologies are based on IP of Sheba Medical Center's (Israel) and Cedar Sinai medical center (US).
Bio-XL has the worldwide exclusive license for the commercialization of the technologies
Contact Us
Nahal Snir 15, Yavne, Israel
meir.biom@gmail.com | Tel: +972-549-536-396